Annovis Bio, Inc. (ANVS)

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. Founded in 2008, the company aims to address the underlying causes of these diseases through its innovative approach. Annovis Bio has developed a lead compound, aimed at improving axonal transport, which is pivotal in the transmission of information in nerve cells. As of recent updates, the company's CEO is Maria Maccecchini, Ph.D., who has been instrumental in driving their research and clinical efforts. Annovis Bio is headquartered in Berwyn, Pennsylvania, and while their revenue reflects the typical challenges of a biotech firm in the development stage, they are supported by investors interested in breakthroughs for treating neurodegeneration. The company is seen as a promising contender in the biotech space, especially with growing attention on brain health and neurodegenerative disease treatment.